港股異動 | 獲投行唱好 創科實業(0669.HK)漲逾4%再創新高
格隆匯4月8日丨創科實業(0669.HK)盤中直線拉昇,最高見141港元續創新高,現報139.7港元,漲幅4.3%,最新總市值2560.45億港元。美銀證券指,公司是最具吸引力的長期增長股之一,而且公司正積極擴張,冀於5年內將公司規模增大一倍,進一步拋離競爭對手。憑藉獨一無二的新產品供應,美國消費者準備花費以及潛在的基礎設施刺激,該行認為創科又將迎來輝煌的一年。該行重申“買入”評級,目標價由140港元升至157港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.